IXCells达成iPSC细胞系交付里程碑IXCells Reaches iPSC Line Delivery Milestone

动脉网03-12

iXCells Biotechnologies USA, Inc. a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC)...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618390361?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-12 13:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2618390361","market":"us","top_or_hot":-1,"title":"IXCells达成iPSC细胞系交付里程碑IXCells Reaches iPSC Line Delivery Milestone","media":"动脉网","content":"<div>\n<p>iXCells Biotechnologies USA, Inc. a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC)...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031213531597aee702&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IXCells达成iPSC细胞系交付里程碑IXCells Reaches iPSC Line Delivery Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIXCells达成iPSC细胞系交付里程碑IXCells Reaches iPSC Line Delivery Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 13:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031213531597aee702&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>iXCells Biotechnologies USA, Inc. a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC)...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031213531597aee702&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LINE","symbol_name":"Lineage","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031213531597aee702&s=b","article_id":"2618390361","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031213531597aee702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618390361","pubTimestamp":1773294660,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此次合作利用了iXCells的iPSCore平台，该平台能够大规模生成经过充分鉴定的患者来源iPSC细胞系，以支持新型疗法的发现与开发。The platform supports drug discovery by enabling the creation, characterization and delivery of validated iPSC lines derived from diverse patient cohorts. iPSCore is delivering nearly 200 lines per month, with a reprogramming success rate exceeding 98%, and built-in cell banking at each stage to ensure continuity and mitigate risk.该平台通过支持创建、表征和交付源自不同患者群体的经过验证的iPSC细胞系来助力药物发现。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LINE":"Lineage","BK4224":"工业房地产信托"},"translate_title":"IXCells Reaches iPSC Line Delivery Milestone IXCells Reaches iPSC Line Delivery Milestone","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LINE":0.9},"content_text":"iXCells Biotechnologies USA, Inc. a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The collaboration leverages iXCells’ iPSCore platform, which enables the large-scale generation of well-characterized patient-derived iPSC lines, to support the discovery and development of novel therapeutics..iXCells生物技术美国公司，作为人体细胞解决方案和定制iPSC服务的领先提供商，今天宣布，在与一家全球生物技术公司的多年合作中，已交付超过500株经过鉴定的诱导多能干细胞（iPSC）系。此次合作利用了iXCells的iPSCore平台，该平台能够大规模生成经过充分鉴定的患者来源iPSC细胞系，以支持新型疗法的发现与开发。The platform supports drug discovery by enabling the creation, characterization and delivery of validated iPSC lines derived from diverse patient cohorts. iPSCore is delivering nearly 200 lines per month, with a reprogramming success rate exceeding 98%, and built-in cell banking at each stage to ensure continuity and mitigate risk.该平台通过支持创建、表征和交付源自不同患者群体的经过验证的iPSC细胞系来助力药物发现。iPSCore每月提供近200条细胞系，重编程成功率超过98%，并在每个阶段都设有内置的细胞存储以确保连续性并降低风险。This scale allows researchers to study large patient cohorts, capturing population-level genetic diversity and minimizing background variance, which is critical for understanding complex diseases such as neurodegenerative disorders, oncology, cardiac disorders, or toxicology screening..这种规模使研究人员能够研究大型患者群体，捕获群体水平的遗传多样性并最小化背景差异，这对于理解复杂疾病（如神经退行性疾病、肿瘤学、心脏疾病或毒理学筛查）至关重要。iPSCore platform delivered over 500 characterized iPSC lines during first year of collaborationiPSCore平台在合作的第一年交付了超过500条经过鉴定的iPSC细胞系To date, iXCells has delivered more than 500 characterized patient-derived iPSC lines under the collaboration, with more than 700 additional lines in development, demonstrating the scalability and efficiency of the iPSCore platform. The collaboration demonstrates iXCells’ ability to deliver iPSC reprogramming at industrial scale, enabling high-throughput production of large volumes of patient-derived lines while maintaining quality, reproducibility, and consistency.迄今为止，iXCells在该合作下已经交付了500多条经过鉴定的患者来源的iPSC细胞系，另有700多条正在开发中，展示了iPSCore平台的可扩展性和高效性。此次合作证明了iXCells能够实现工业规模的iPSC重编程，支持高质量、高通量的大批量患者来源细胞系生产，同时确保质量、可重复性和一致性。Further projects as part of the collaboration will expand the scale of the platform, including for differentiated cell types and disease-relevant models..作为合作的一部分，进一步的项目将扩大平台的规模，包括针对不同细胞类型和与疾病相关的模型。The generation of validated iPSC lines using iPSCore is particularly meaningful in complex therapeutic areas where understanding patient diversity and disease biology is crucial. By enabling scalable access to high-quality, cohort-based iPSC models, iXCells is supporting researchers to generate comprehensive, population-relevant data sets, accelerating target identification and optimizing therapeutic strategies.使用iPSCore生成经过验证的iPSC细胞系在复杂的治疗领域中具有特别重要的意义，因为在这些领域中，了解患者多样性和疾病生物学至关重要。通过提供对高质量、基于队列的iPSC模型的可扩展访问，iXCells正在支持研究人员生成全面的、与人群相关的数据集，加速靶点识别并优化治疗策略。Scaling Patient-Derived iPSC Models for Better Drug Discovery扩展患者来源的iPSC模型以促进更好的药物发现Steve Smith, CEO at iXCells Biotechnologies, said: “Reliable, large-scale access to patient-relevant cell models is revolutionizing our approach to disease research. By reaching this milestone in our collaboration, we are demonstrating that the right expertise and infrastructure can empower discovery teams to leverage diverse data from the very start, enabling delivering iPSC models at scale and dramatically improving the likelihood of successful drug development.iXCells生物技术公司的首席执行官史蒂夫·史密斯表示：“可靠且大规模获取与患者相关的细胞模型正在彻底改变我们对疾病研究的方法。通过在我们的合作中达到这一里程碑，我们证明了正确的专业知识和基础设施能够助力发现团队从一开始就利用多样化的数据，从而实现大规模交付iPSC模型，并显著提高药物开发成功的可能性。”Ongoing expansion of our iPSCore platform capabilities will enable large-scale access to high quality patient-derived human cell models to drive breakthroughs in drug discovery.”.“我们iPSCore平台能力的持续扩展将使大规模获取高质量患者来源的人类细胞模型成为可能，从而推动药物发现的突破。”Alex Gulotta, Board of Directors, iXCells Biotechnologies commented: ” iXCells’ commitment to industrialization has fundamentally shifted the paradigm in drug discovery. Embedding patient-derived human cell models as foundational infrastructure throughout the drug development process enables hypothesis testing that truly reflects patient biology.Alex Gulotta，iXCells生物技术公司董事会成员评论道：“iXCells对产业化的承诺从根本上转变了药物发现的范式。将患者来源的人类细胞模型作为整个药物开发过程的基础架构，能够实现真正反映患者生物学特性的假设测试。”What iXCells has built in iPSCore, and demonstrated through this collaboration, is exactly the kind of validated, scalable, revenue-generating platform that the industry needs and acquirers are looking for. This supports smarter, earlier decision-making, reducing costly late-stage failures and mitigating risk for stakeholders and partners.”.iXCells在iPSCore中构建并通过此次合作展示的，正是行业所需、收购者所寻找的经过验证的、可扩展的、能产生收入的平台。这有助于更明智、更早期的决策，减少昂贵的后期失败，并降低利益相关者和合作伙伴的风险。\"About iXCells Biotechnologies关于iXCells生物技术iXCells Biotechnologies (“iXCells”) is a leading San Diego, California-based cell technology company focused on generating a wide variety of predictive human disease models. In addition, iXCells is pursuing custom and patient-specific services leveraging its expertise in the preparation, handling, engineering and differentiation of induced pluripotent stem cells (iPSCs) and in the isolation of primary cells along with associated services for descriptive and functional cell characterization, compound screening and toxicology testing..iXCells生物技术公司（“iXCells”）是一家位于加利福尼亚州圣地亚哥的领先细胞技术公司，专注于生成各种预测性人类疾病模型。此外，iXCells利用其在诱导多能干细胞（iPSCs）的制备、处理、工程化和分化以及原代细胞分离方面的专业知识，提供定制和患者特定的服务，并提供相关的描述性和功能性细胞表征、化合物筛选和毒理学测试服务。The company’s mission is to supply a diverse range of human disease models, derived from ethically sourced patient and healthy donor tissues, to support academic, pharmaceutical, and clinical researchers globally. By providing predictive human cell models, we aim to deepen the understanding of the molecular mechanisms underlying disease onset and progression as much as slow-down or reversion of disease, and accelerate the discovery and development of new medicines and innovative therapies to further advance precision medicine..公司的使命是提供多种人类疾病模型，这些模型源自符合伦理的患者和健康捐赠者的组织，以支持全球学术界、制药界和临床研究人员。通过提供可预测的人类细胞模型，我们旨在深入理解疾病发生和进展以及减缓或逆转疾病的分子机制，并加速新药和创新疗法的发现与开发，从而进一步推动精准医疗的发展。Media Contacts媒体联系人Christy Holt克里斯蒂·霍尔特VP, Marketing and Sales副总裁，市场营销与销售christy.holt@ixcellsbiotech.comchristy.holt@ixcellsbiotech.comiXCellsBiotech.comiXCells生物技术公司Source: ixcellsbiotech.com来源：ixcellsbiotech.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618390361","isCrawlerRequest":true}